Abbott Laboratories 2012 Annual Report Download - page 24

Download and view the complete annual report

Please find page 24 of the 2012 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

BROAD
AND
COMPELLING.
ABBVIE HAS AN EXCITING MID-
AND LATE-STAGE PIPELINE CONTAINING
NUMEROUS MEDICINES WITH
BREAKTHROUGH POTENTIAL IN
IMPORTANT AREAS OF MEDICAL NEED.
30 14
IMMUNOLOGY
THE ABBVIE PIPELINE
biologic compounds
across several
therapeutic areas
compounds currently
in human trials
By focusing research in areas of signicant unmet need, and
in those where its expertise oers the greatest chance for
success, AbbVie has amassed a pipeline lled with promising
compounds. With 30 candidates currently in human trials,
including 20 in mid- or late-stage development, AbbVie is
poised to deliver breakthroughs in important treatment
areas. AbbVie’s eorts in virology center on the hepatitis C
virus (HCV), which aects 170 million people worldwide.
In oncology, AbbVie’s research is focused on therapies that
may change the way the disease behaves. Its immunology
programs include work in oral disease-modifying therapies
and biologics, as well as proprietary combination biologic
agents. In neuroscience, AbbVie has multiple small
molecules and biologics designed to treat a variety of
conditions, including multiple sclerosis, Parkinson’s disease,
schizophrenia, Alzheimer’s disease, and acute and chronic
pain. AbbVie is also building its expertise in women’s
health with a promising compound in development for
endometriosis and uterine broids.
Across a broad spectrum of treatment areas.
Including a number of proprietary
combination biologic agents.
22
Abbott 2012 Annual Report